


07-01-1999



101080652
RECORDATION FORM COVER SHEET
PATENTS ONLY

U.S. Department of Commerce
Patent and Trademark Office



TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

☒ New **6.29.99**
☐ Resubmission (Non-Recordation)
Document ID#
☐ Correction of PTO Error
Reel # Frame #
☐ Corrective Document
Reel # Frame #

Conveyance Type

☐ Assignment ☐ Security Agreement
☐ License ☐ Change of Name
☐ Merger ☒ Other Termination of Security Interest
U.S. Government
(For Use ONLY by U.S. Government Agencies)
☐ Departmental File ☐ Secret File

Conveying Party(ies)

☐ Mark if additional names of conveying parties attached
Name (line 1) HEMOCLEANSE, INC.
Name (line 2) an Indiana corporation
Execution Date Month Day Year 04 30 1999

Second Party

Name (line 1)
Name (line 2)
Execution Date Month Day Year

Receiving Party

☐ Mark if additional names of receiving parties attached
Name (line 1) Infectious Disease Treatment Corporation
Name (line 2) a Florida corporation
Address (line 1) Building 2500, 2nd Floor
Address (line 2) 2272 Swallow Hill Road
Address (line 3) Pittsburgh PA/USA 15220
City State/Country Zip Code
☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name
Address (line 1)
Address (line 2)
Address (line 3)
Address (line 4)

06/30/1999 BNGUYEN 00000287 08683678

FOR OFFICE USE ONLY


01 FC:581

120.00 OP

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

PATENT
REEL: 010052 FRAME: 0844



Correspondent Name and Address

Area Code and Telephone Number (412) 429-0671

Name Glenn Keeling, President

Address (line 1) IDT, Inc.

Address (line 2) Building 2500, 2nd Floor

Address (line 3) 2275 Swallow Hill Road

Address (line 4) Pittsburgh, PA 15220

Pages

Enter the total number of pages of the attached conveyance document including any attachments.

04

Application Number(s) or Patent Number(s)

☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)

08683678

Patent Number(s)

5536412

5277820

If this document is being filed together with a new Patent Application, enter the date the patent application was signed by the first named executing inventor.

Month Day Year

Patent Cooperation Treaty (PCT)

Enter PCT application number only if a U.S. Application Number has not been assigned.

PCT

PCT

Number of Properties

Enter the total number of properties involved.

03

Fee Amount

Fee Amount for Properties Listed (37 CFR 3.41): \$ 120.00

Method of Payment:
Deposit Account

Enclosed ☒ Deposit Account ☐

(Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number:

#

Authorization to charge additional fees:

Yes

No

Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

HemoCleanse, Inc.

Robert B. Truitt, President & CEO

Name of Person Signing

Signature

Date

RELEASE

This Release (the "Release") is made as of the 30th day of April, 1999 between Infectious Disease Treatment Corp., a Florida corporation (hereinafter referred to as "IDT"), and HemoCleanse, Inc., an Indiana corporation (hereinafter referred to as the "Company").

WHEREAS, the Company granted to IDT a security interest in certain patents, patent applications, trademarks, trademark registrations, trade names, trademark applications, service marks, service mark registrations, licenses relating to the foregoing and certain other intellectual property (collectively, the "Collateral") pursuant to a certain 20% Convertible Promissory Note ("1998 Bridge Note") dated as of April 1, 1998 executed by the Company and accepted by IDT and recorded with the United States Patent and Trademark Office on Reel 009138, Frame 0529;

WHEREAS, IDT has agreed to release all of the rights and interests granted to IDT by the Company under the Patent and Trademark Agreements in consideration for payment in full of all obligations owed by the Company to IDT;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Company and IDT hereby agree as follows:

1. Subject to the terms herein, IDT hereby releases all security interests granted to IDT in the Collateral.
2. This Release is made by IDT without any representation or warranty by, or recourse to, IDT, and the Company shall pay and save IDT harmless against all costs, expenses and liabilities which may be incurred by IDT in connection with this Release.
3. This Release may be executed in any number of counterparts which when taken together shall be deemed to constitute one and the same document and delivery hereof may be made by facsimile transmission.
4. This Release shall be governed by and construed in accordance with Federal law and, to the extent applicable, the internal laws (as opposed to the conflict of law principles) of the State of Indiana.

IN WITNESS WHEREOF, IDT and the Company have caused this Release to be executed by their duly authorized officers as of the date first above written.

Infectious Disease Treatment Corp.

By: Glenn Keeling
Glenn Keeling
Title: President

HemoCleanse, Inc.

By: Robert B. Truitt
Robert B. Truitt
Title: President and CEO